Francesco Cortiula

Medical Oncologist- #lungcancer #thoracic #oncology #protontherapy @UdineUniversityHospital
PhD candidate @MaastrichtU @MaastrichtUMC @MAASTRO

[Francesco Cortiula @FCortiula]

Can we de-escalate ICIs in NSCLC?💡
Are we ready to reduce financial and patients' tox?🔎

Honoured to work on this topic with terrific colleagues
@HendriksLizza @JordiRemon @JessicaMenis @g_mountzios @BenjaminBesseMD @MarianaBrandao0 @NReguart @MartinaBortolot

[Jarushka Naidoo @DrJNaidoo]

De-Escalation Strategies With ICIs in NSCLC: Do We Already Have Enough Evidence? @JCO_ASCO

Pleased to contribute to this great review led by @JordiRemon @GustaveRoussy @OncoAlert @g_mountzios @HendriksLizza @FCortiula @JessicaMenis @MarianaBrandao0 #LCSM https://t.co/c8FeLoMyPL

[Jordi Remon @JordiRemon]

ANVIL: ADJ Nivolumab not ⬆️DFS vs BSC in IB/III NSCLC even in high PDL1 Heterogenous data with ADJ IO. No quality of surgery & good staging (PET/🧠) across trials.
No tumor ➡️ADJ IO not work
Do These negative results raise concerns about Role of ADJ after NEOADJ CTIO?#ASCO26

[Dr. Antonio Calles 🫁🚭 @Tony_Calles]

Pasi Janne presents overall survival by prognostic factors in FLAURA-2 trial of Osimertinib + chemo vs osi alone. Nicely summarized in his last slide. #ESMO25 #LCSM

[Jordi Remon @JordiRemon]

ALEX trial 1st L alectinib (vs crizo) not ⬆️OS but trial not powered for OS. The best drug first? living w/o disease PD and good control of risk of brain PD count most!!Today lorlatinib is one SoC, futute SoC in 1st line Neladalkib (NVL655), ALKZAR trial vs alectinib?. #ESMO25

[Jordi Remon @JordiRemon]

Zipalertinib in EGFRex20ins NSCLC reported 31% of intracranial ORR 🧠. Today crowded space of TKI for EGFRex20ins. New SoC? Best sequence? Brain activity and toxicity relevant for 1st Line decision. #ESMO25

[Medthority @Medthority]

Session opens with a case of stage IIIB #NSCLC in a frail 76-year-old. The MDT recommends sequential chemoradiotherapy. @FCortiula asks:
❓Can we de-escalate without losing radical intent?
❓Can immunotherapy reduce toxicity?
❓Can we tailor treatment to response?
#ESMO25 #MedX

[Lodovica Zullo @LodovicaZullo]

Italian National Team at #WCLC2025 @AriMarinel @RobertoFerrara_ @Max_Cani @Gmazzaschi90 @pecci_federica1 @doctordegio @CarloGenova5 and many others 🇮🇹🍕

[Society for Immunotherapy of Cancer @sitcancer]

Discuss a wide range of case studies with leading experts! Access practical cancer IO insights at @sitcancer’s #virtual ACI: A Focus on Lung Cancers program Sept. 12. View topics: https://t.co/7aGu6hKmR5

@ChaftJamie @FCortiula @DrJNaidoo @drshieldsmd
#LearnACI

[Stephen V Liu, MD @StephenVLiu]

Press release updates data for NVL-520, zidesamtinib, in #ROS1 NSCLC. In 117 pts who had prior TKI (half had 2+ TKIs), RR 44% with 78% ongoing after one year. Intracranial efficacy and active in ROS1 G2032R. Tolerability: discontinuation rate only 2%!

https://t.co/jshs9bMRSD

[ESMO - Eur. Oncology @myESMO]

📣Updated ESMO #ClinicalPracticeGuideline recommendations in oncogene-addicted metastatic #NSCLC: more #TargetedTherapy agents now available in 1L or at resistance.
#LungCancer #mNSCLC #ESMOGuidelines

🔗 https://t.co/Ns4jjSTo3e

[ESMO - Eur. Oncology @myESMO]

📣Updated ESMO #ClinicalPracticeGuideline recommendations in the non-oncogene-addicted metastatic #NSCLC: new 1L Tx options approved.

🔗 https://t.co/S04MDA13Jn

#LungCancer #mNSCLC #ESMOGuidelines

[Jarushka Naidoo @DrJNaidoo]

#ASCO25 Developmental Therapeutics CSS🔥

Ph III DELLI trial: ultra-low dose nivo in 2L all solid tumors v chemo @VanitaNoronha @TataMemorial:
- 500pts
- OS HR 0.80 (p=0.02, NS primary endpt HR 0.75)
- no diff in PFS/ORR/tox

A brave trial, next step evaluate chemoIO? @asco

[Jonathan Spicer MD PhD @DoctorJSpicer]

Why is CM816 so important? After @FordePatrick beautiful presentation of these revolutionary data, let’s dig into why this unique trial should shake up our vision for oncology research…

[Stephen V Liu, MD @StephenVLiu]

#ASCO25 Dr. @charlesrudin presents interim analysis of DeLLphi-304: randomized phase II study of tarlatamab (DLL3 TCE) vs 2L chemo in #SCLC. Chemo was mostly topotecan; 45% of pts were platinum resistant. Clear OS benefit with HR 0.60 (13.6m vs 8.3m). PFS 4.2 vs 3.7m, HR 0.71.

[Tom Newsom-Davis @tnewsomdavis]

IMforte: lurbinectedin + atezo maintenance ES-SCLC

✅ ⬆️ mPFS 5.4 v 2.1m, HR 0.54
✅ ⬆️ mOS 13.2 v 10.6m, HR 0.73
✅ ⬆️ ORR 19% v 10%

🔺Gr3+ AE 25% v 5%
🔺 Myelosupression, N&V, fatigue

🤔 Active combo, at cost of toxicity
🤔 OS impressive = 16m from diagnosis

#LCSM #ASCO25

[Patrick Forde @FordePatrick]

Remarkable results in pretreated EGFR mutant lung cancer! In global trial, stellar benefit in progression-free survival for the addition of ivonescimab to platinum doublet chemo. Given tox profile may be a preferred option in this setting. #LCSM #ASCO25

[Jarushka Naidoo @DrJNaidoo]

Fascinating paper @NatureCancer on mechanisms of resistance to TIL in NSCLC:

- serial multiomic analysis, 16pt TIL trial
- subclonal neoAg lost at progression
- LOH of pMHC in KRAS-specific Tcells at progression

@BenCreelan @MoffittNews @OncoAlert #LCSM https://t.co/p7jYl5l546

[Aakash Desai, MD, MPH, FASCO @ADesaiMD]

In @JTOonline #BRAF-mutated #NSCLC: https://t.co/mo2dvSVXSJ
📊 1L targeted therapy (dabrafenib/trametinib) vs. chemo-IO shows:
➖ Similar OS outcomes
➖ PD-L1 status & gender influence prognosis
🎯 Personalization > one-size-fits-all
@LungCancerRx @oncodaily @OncBrothers

[Francesco Cortiula @FCortiula]

Congrats to all the authors for this great collaborative effort🏆

ICI retreatment after durvalumab for relapsed stage III NSCLC should be offered to selected patients💥📢

These results also confirm our previous findings🎯
@HendriksLizza
@AndrearicFili

https://t.co/UMmzRt3Gz3

[Stephen V Liu, MD @StephenVLiu]

Real world outcomes in pts with relapse after durvalumab consolidation post CRT for stage III NSCLC @LungCaJournal. With chemo-immunotherapy, PFS 12m; with platinum-based chemo alone, PFS 4.1m; non-platinum based chemo PFS 2.7m; targeted therapy PFS 6m.

https://t.co/ffVX9For3h

[Jordi Remon @JordiRemon]

Personalised approach at osimertinib PD with savolitinib and osimertinib in MET deregulated EGFRm NSCLC looks promising. Is it better than CT+Ami or ADC? Hwr, it is a chemofree strategy and other treatments could be applied later #ELCC25

[Jordi Remon @JordiRemon]

We had efficacy data ADCs after osi-PD in EGFRm NSCLC. Today good mPFS (9.5-11.7) with Osi+DatopotamAb Dxd after osi-PD. Data looks ➕promising than chemo+Amiv. Better 🧠 protection maintaining osi? Biomarker for dato? Toxicity is imp. Future trial: osi-DATOD vs Ami-CT? #ELCC25